Richard Greil

Research interests

Publications

• Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

  The Lancet Oncology · 2024 · https://doi.org/10.1016/s1470-2045(24)00100-1

• Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

  The Lancet Oncology · 2024 · https://doi.org/10.1016/s1470-2045(24)00100-1

• Spatial predictors of immunotherapy response in triple-negative breast cancer

  Nature · 2023 · https://doi.org/10.1038/s41586-023-06498-3

• Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study

  Journal of Clinical Oncology · 2022 · https://doi.org/10.1200/jco.21.02508

• Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

  Annals of Oncology · 2022 · https://doi.org/10.1016/j.annonc.2022.09.159

• Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study

  Annals of Oncology · 2022 · https://doi.org/10.1016/j.annonc.2022.02.004

• Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial

  The Lancet Oncology · 2022 · https://doi.org/10.1016/s1470-2045(22)00293-5

• Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer

  New England Journal of Medicine · 2021 · https://doi.org/10.1056/nejmoa2104162

• Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)

  Journal of Clinical Oncology · 2021 · https://doi.org/10.1200/jco.21.02554

• Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study

  The Lancet Haematology · 2020 · 10.1016/s2352-3026(19)30236-4

• Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial

  The Lancet Oncology · 2020 · 10.1016/s1470-2045(20)30321-1

• Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1914609

• Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

  The Lancet · 2019 · https://doi.org/10.1016/s0140-6736(19)32591-7

• Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

  The Lancet Oncology · 2018 · 10.1016/s1470-2045(18)30788-5

• Impact of Breast Surgery in Primary Metastasized Breast Cancer

  Annals of Surgery · 2018 · https://doi.org/10.1097/sla.0000000000002771

• PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group

  The Lancet · 2017 · 10.1016/s0140-6736(17)32134-7

• Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial

  The Lancet · 2015 · https://doi.org/10.1016/s0140-6736(15)60995-3

• Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12

  Annals of Oncology · 2014 · https://doi.org/10.1093/annonc/mdu544

• Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone

  Annals of Oncology · 2013 · https://doi.org/10.1093/annonc/mdt494

• Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer

  Journal of Clinical Oncology · 2013 · https://doi.org/10.1200/jco.2012.46.2408

• Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial

  The Lancet · 2012 · 10.1016/s0140-6736(11)61940-5

• Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

  The Lancet Oncology · 2012 · https://doi.org/10.1016/s1470-2045(12)70477-1

• A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors

  Clinical Cancer Research · 2011 · 10.1158/1078-0432.ccr-11-0926

• Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial

  The Lancet Oncology · 2011 · 10.1016/s1470-2045(11)70122-x

• Intensified Chemotherapy and Dose-Reduced Involved-Field Radiotherapy in Patients With Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD11 Trial

  Journal of Clinical Oncology · 2010 · https://doi.org/10.1200/jco.2010.29.8018

• Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma

  New England Journal of Medicine · 2010 · 10.1056/nejmoa1000067

• Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer

  Journal of Clinical Oncology · 2009 · 10.1200/jco.2008.18.8391

• Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer

  New England Journal of Medicine · 2009 · https://doi.org/10.1056/nejmoa0806285

• Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer

  Clinical Cancer Research · 2009 · 10.1158/1078-0432.ccr-08-1080

• Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3

  Journal of Clinical Oncology · 2009 · 10.1200/jco.2008.21.6663

• Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy

  The Lancet Oncology · 2008 · 10.1016/s1470-2045(08)70204-3

• Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial

  The Lancet · 2005 · 10.1016/s0140-6736(05)67059-6

• Normative data for functional assessment of cancer therapy General scale and its use for the interpretation of quality of life scores in cancer survivors

  Acta Oncologica · 2004 · https://doi.org/10.1080/02841860310023453

• Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response

  Blood · 1995 · https://doi.org/10.1182/blood.v86.12.4446.bloodjournal86124446

Current projects

No projects listed.